Search

Your search keyword '"Novellino, Fabiana"' showing total 303 results
Start Over Author "Novellino, Fabiana"
303 results on '"Novellino, Fabiana"'

11. Imaging counterpart of postural instability and vertical ocular dysfunction in patients with PSP: A multimodal MRI study

Author

Quattrone, Andrea, Caligiuri, Maria Eugenia, Morelli, Maurizio, Nigro, Salvatore, Vescio, Basilio, Arabia, Gennarina, Nicoletti, Giuseppe, Nisticò, Rita, Salsone, Maria, Novellino, Fabiana, Barbagallo, Gaetano, Vaccaro, Maria Grazia, Sabatini, Umberto, Vescio, Virginia, Stanà, Carlo, Rocca, Federico, Caracciolo, Manuela, and Quattrone, Aldo

Published
2019
Full Text
View/download PDF

14. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease

Author

Quattrone, Aldo, Morelli, Maurizio, Nigro, Salvatore, Quattrone, Andrea, Vescio, Basilio, Arabia, Gennarina, Nicoletti, Giuseppe, Nisticò, Rita, Salsone, Maria, Novellino, Fabiana, Barbagallo, Gaetano, Le Piane, Emilio, Pugliese, Pierfrancesco, Bosco, Domenico, Vaccaro, Maria Grazia, Chiriaco, Carmelina, Sabatini, Umberto, Vescio, Virginia, Stanà, Carlo, Rocca, Federico, Gullà, Domenico, and Caracciolo, Manuela

Published
2018
Full Text
View/download PDF

22. A data‐driven approach to neuropsychological features in isolated REM behaviour disorder: A latent class analysis

Author

Mombelli, Samantha, primary, Leitner, Caterina, additional, D'Este, Giada, additional, Sforza, Marco, additional, Marelli, Sara, additional, Castelnuovo, Alessandra, additional, Zucconi, Marco, additional, Casoni, Francesca, additional, Fantini, Maria Livia, additional, Novellino, Fabiana, additional, Salsone, Maria, additional, Ferini‐Strambi, Luigi, additional, and Galbiati, Andrea, additional

Published
2022
Full Text
View/download PDF

26. CCL2 Inhibition of Pro-Resolving Mediators Potentiates Neuroinflammation in Astrocytes

Author

López Gutiérrez, Irene, Novellino, Fabiana, Caso Fernández, Javier Rubén, García Bueno, Borja, Leza Cerro, Juan Carlos, Muñoz Madrigal, José Luis, López Gutiérrez, Irene, Novellino, Fabiana, Caso Fernández, Javier Rubén, García Bueno, Borja, Leza Cerro, Juan Carlos, and Muñoz Madrigal, José Luis

Abstract

The chemokine CCL2 participates in multiple neuroinflammatory processes, mainly through the recruitment of glial cells. However, CCL2 has also been proven to exert different types of actions on these cells, including the modification of their response to inflammatory stimuli. In the present study we analyzed the effect of CCL2 on the resolution of inflammation in astrocytes. We observed that genetic removal of CCL2 increases the expression of the enzymes responsible for the synthesis of specialized pro-resolving mediators arachidonate 15-lipoxygenase and arachidonate 5-lipoxygenase in the brain cortex of 5xFAD mice. The expression of FPR2 receptor, known to mediate the activity of pro-resolving mediators was also increased in mice lacking CCL2.The downregulation of these proteins by CCL2 was also observed in cultured astrocytes. This suggests that CCL2 inhibition of the resolution of inflammation could facilitate the progression of neuroinflammatory processes. The production of the pro-inflammatory cytokine IL-1beta by astrocytes was analyzed, and allowed us to confirm that CCL2 potentiates the activation of astrocytes trough the inhibition of pro-resolving pathways mediated by Resolvin D1. In addition, the analysis of the expression of TNFalpha, MIP1alpha and NOS2 further confirmed CCL2 inhibition of inflammation resolution in astrocytes., Ministerio de Ciencia e Innovación (MICINN), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Depto. de Farmacología y Toxicología, Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2022

27. Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target

Author

López Gutiérrez, Irene, Novellino, Fabiana, Caso Fernández, Javier Rubén, García Bueno, Borja, Leza Cerro, Juan Carlos, Muñoz Madrigal, José Luis, López Gutiérrez, Irene, Novellino, Fabiana, Caso Fernández, Javier Rubén, García Bueno, Borja, Leza Cerro, Juan Carlos, and Muñoz Madrigal, José Luis

Abstract

A growing body of evidence demonstrates the important role of the noradrenergic system in the pathogenesis of many neurodegenerative processes, especially Alzheimer’s disease, due to its ability to control glial activation and chemokine production resulting in anti-inflammatory and neuroprotective effects. Noradrenaline involvement in this disease was first proposed after finding deficits of noradrenergic neurons in the locus coeruleus from Alzheimer’s disease patients. Based on this, it has been hypothesized that the early loss of noradrenergic projections and the subsequent reduction of noradrenaline brain levels contribute to cognitive dysfunctions and the progression of neurodegeneration. Several studies have focused on analyzing the role of noradrenaline in the development and progression of Alzheimer’s disease. In this review we summarize some of the most relevant data describing the alterations of the noradrenergic system normally occurring in Alzheimer’s disease as well as experimental studies in which noradrenaline concentration was modified in order to further analyze how these alterations affect the behavior and viability of different nervous cells. The combination of the different studies here presented suggests that the maintenance of adequate noradrenaline levels in the central nervous system constitutes a key factor of the endogenous defense systems that help prevent or delay the development of Alzheimer’s disease. For this reason, the use of noradrenaline modulating drugs is proposed as an interesting alternative therapeutic option for Alzheimer’s disease., Ministerio de Ciencia e Innovación (MICCIN), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)., Depto. de Farmacología y Toxicología, Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2022

28. Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target

Author

Gutiérrez, Irene L, Dello Russo, Cinzia, Novellino, Fabiana, Caso, Javier R, García-Bueno, Borja, Leza, Juan C, Madrigal, José L M, Dello Russo, Cinzia (ORCID:0000-0002-2538-3832), Gutiérrez, Irene L, Dello Russo, Cinzia, Novellino, Fabiana, Caso, Javier R, García-Bueno, Borja, Leza, Juan C, Madrigal, José L M, and Dello Russo, Cinzia (ORCID:0000-0002-2538-3832)

Abstract

A growing body of evidence demonstrates the important role of the noradrenergic system in the pathogenesis of many neurodegenerative processes, especially Alzheimer's disease, due to its ability to control glial activation and chemokine production resulting in anti-inflammatory and neuroprotective effects. Noradrenaline involvement in this disease was first proposed after finding deficits of noradrenergic neurons in the locus coeruleus from Alzheimer's disease patients. Based on this, it has been hypothesized that the early loss of noradrenergic projections and the subsequent reduction of noradrenaline brain levels contribute to cognitive dysfunctions and the progression of neurodegeneration. Several studies have focused on analyzing the role of noradrenaline in the development and progression of Alzheimer's disease. In this review we summarize some of the most relevant data describing the alterations of the noradrenergic system normally occurring in Alzheimer's disease as well as experimental studies in which noradrenaline concentration was modified in order to further analyze how these alterations affect the behavior and viability of different nervous cells. The combination of the different studies here presented suggests that the maintenance of adequate noradrenaline levels in the central nervous system constitutes a key factor of the endogenous defense systems that help prevent or delay the development of Alzheimer's disease. For this reason, the use of noradrenaline modulating drugs is proposed as an interesting alternative therapeutic option for Alzheimer's disease.

Published
2022

30. A data‐driven approach to neuropsychological features in isolated REM behaviour disorder: A latent class analysis.

Author

Mombelli, Samantha, Leitner, Caterina, D'Este, Giada, Sforza, Marco, Marelli, Sara, Castelnuovo, Alessandra, Zucconi, Marco, Casoni, Francesca, Fantini, Maria Livia, Novellino, Fabiana, Salsone, Maria, Ferini‐Strambi, Luigi, and Galbiati, Andrea

Subjects
BEHAVIOR disorders, EXECUTIVE function, NEUROPSYCHOLOGICAL tests, LONG-term memory, MILD cognitive impairment
Abstract

Recent evidence demonstrated that neuropsychological assessment may be considered a valid marker of neurodegeneration in idiopathic REM sleep behaviour disorder (iRBD). However, little is known about the possible neuropsychological heterogeneity within the iRBD population. This retrospective study aimed to identify and describe different neuropsychological phenotypes in iRBD patients by means of a data‐driven approach using latent class analysis. A total of 289 iRBD patients underwent a neuropsychological assessment evaluating cognitive domains: global cognition, language, short‐ and long‐term memory, executive functions and visuospatial abilities. The presence of mild cognitive impairment (MCI) was also assessed. Latent class analysis was carried out to identify iRBD subtypes according to neuropsychological scores. The most parsimonious model identified three latent classes. Groups were labelled as follows: Class 2 "severely impaired" (n = 83/289): mean pathological scores in different tests, a high percentage of MCI multiple‐domain and impairment in all neuropsychological domains. Class 1 "moderately impaired" (n = 44/289): mean neuropsychological score within the normal value, a high percentage of MCI (high risk to phenoconversion) and great impairment in the visuospatial domain. Class 3 "slightly impaired" (n = 162/289): no deficit worthy of attention except for short‐ and long‐term memory. Our results suggest three different clinical phenotypes within the iRBD population. These findings may be relevant in the future for predicting the clinical trajectories of phenoconversion in iRBD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Refining initial diagnosis of Parkinson's disease after follow‐up: A 4‐year prospective clinical and magnetic resonance imaging study

Author

Quattrone, Aldo, Morelli, Maurizio, Vescio, Basilio, Nigro, Salvatore, Le Piane, Emilio, Sabatini, Umberto, Caracciolo, Manuela, Vescio, Virginia, Quattrone, Andrea, Barbagallo, Gaetano, Stanà, Carlo, Nicoletti, Giuseppe, Arabia, Gennarina, Nisticò, Rita, Novellino, Fabiana, and Salsone, Maria

Subjects
Adult, Aged, 80 and over, Male, progressive supranuclear palsy‐parkinsonism, magnetic Resonance Parkinsonism Index 2.0, vertical gaze abnormalities, Brain, Parkinson Disease, Middle Aged, Magnetic Resonance Imaging, Diagnosis, Differential, Image Processing, Computer-Assisted, Humans, Female, Supranuclear Palsy, Progressive, Diagnostic Errors, magnetic resonance parkinsonism index, Research Articles, Research Article, pons/midbrain area ratio 2.0, Aged
Abstract

Background No prospective study of patients with Parkinson's disease (PD) has investigated the appearance of vertical gaze abnormalities, a feature suggestive of progressive supranuclear palsy (PSP). Objective To identify, within a cohort of patients with an initial diagnosis of PD, those who developed vertical gaze abnormalities during a 4‐year follow‐up, and to investigate the performance of new imaging biomarkers in predicting vertical gaze abnormalities. Methods A total of 110 patients initially classified as PD and 74 controls were enrolled. All patients underwent clinical assessment at baseline and every year up to the end of the follow‐up. The pons/midbrain area ratio 2.0 and the Magnetic Resonance Parkinsonism Index 2.0 were calculated. Results After 4‐year follow‐up, 100 of 110 patients maintained the diagnosis of PD, whereas 10 PD patients (9.1%) developed vertical gaze abnormalities, suggesting an alternative diagnosis of PSP‐parkinsonism. At baseline, the Magnetic Resonance Parkinsonism Index 2.0 was the most accurate biomarker in differentiating PD patients who developed vertical gaze abnormalities from those who maintained an initial diagnosis of PD. At the end of follow‐up, both of these biomarkers accurately distinguished PSP‐parkinsonism from PD. Conclusions Our results demonstrate that a number of patients with an initial diagnosis of PD developed vertical gaze abnormalities during a 4‐year follow‐up, and the diagnosis was changed from PD to PSP‐parkinsonism. In PD patients, baseline Magnetic Resonance Parkinsonism Index 2.0 showed the best performance in predicting the clinical evolution toward a PSP‐parkinsonism phenotype, enabling PSP‐parkinsonism patients to be identified at the earliest stage of the disease for promising disease‐modifying therapies. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Published
2019

42. Cardiac MIBG scintigraphy in Primary Progressive Freezing Gait

Author

Salsone, Maria, Bagnato, Antonio, Novellino, Fabiana, Cascini, Giuseppe Lucio, Paglionico, Sandra, Cipullo, Stefania, Morelli, Maurizio, Pugliese, Pierfrancesco, Nicoletti, Giuseppe, Messina, Demetrio, Condino, Francesca, Arabia, Gennarina, Morgante, Letterio, and Quattrone, Aldo

Published
2009
Full Text
View/download PDF

46. A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies

Author

Nalls, Michael A., Duran, Raquel, Lopez, Grisel, Kurzawa-Akanbi, Marzena, McKeith, Ian G., Chinnery, Patrick F., Morris, Christopher M., Theuns, Jessie, Crosiers, David, Cras, Patrick, Engelborghs, Sebastiaan, De Deyn, Peter Paul, Van Broeckhoven, Christine, Mann, David M., Snowden, Julie, Pickering-Brown, Stuart, Halliwell, Nicola, Davidson, Yvonne, Gibbons, Linda, Harris, Jenny, Sheerin, Una-Marie, Bras, Jose, Hardy, John, Clark, Lorraine, Marder, Karen, Honig, Lawrence S., Berg, Daniela, Maetzler, Walter, Brockmann, Kathrin, Gasser, Thomas, Novellino, Fabiana, Quattrone, Aldo, Annesi, Grazia, De Marco, Elvira Valeria, Rogaeva, Ekaterina, Masellis, Mario, Black, Sandra E., Bilbao, Juan M., Foroud, Tatiana, Ghetti, Bernardino, Nichols, William C., Pankratz, Nathan, Halliday, Glenda, Lesage, Suzanne, Klebe, Stephan, Durr, Alexandra, Duyckaerts, Charles, Brice, Alexis, Giasson, Benoit I., Trojanowski, John Q., Hurtig, Howard I., Tayebi, Nahid, Landazabal, Claudia, Knight, Melanie A., Keller, Margaux, Singleton, Andrew B., Wolfsberg, Tyra G., and Sidransky, Ellen

Published
2013
Full Text
View/download PDF

48. Association study between four polymorphisms in the HFE, TF and TFR genes and Parkinson’s disease in Southern Italy

Author

Greco, Valentina, De Marco, Elvira Valeria, Rocca, Francesca Emanuela, Annesi, Ferdinanda, Civitelli, Donatella, Provenzano, Giovanni, Tarantino, Patrizia, Scornaienchi, Vittorio, Pucci, Franco, Salsone, Maria, Novellino, Fabiana, Morelli, Maurizio, Paglionico, Sandra, Gambardella, Antonio, Quattrone, Aldo, and Annesi, Grazia

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results